EX-597 (former developmental code names URB-597, KDS-4103, and ORG-231295) is a fatty acid amide hydrolase inhibitor (FAAH inhibitor) which is under development for the treatment of social anxiety disorder (or social phobia) and post-traumatic stress disorder (PTSD).
EX-597 (former developmental code names URB-597, KDS-4103, and ORG-231295) is a fatty acid amide hydrolase inhibitor (FAAH inhibitor) which is under development for the treatment of social anxiety disorder (or social phobia) and post-traumatic stress disorder (PTSD).
It is a relatively selective and irreversible inhibitor of the enzyme fatty acid amide hydrolase (FAAH). FAAH is the primary degradatory enzyme for the endocannabinoid anandamide and, as such, inhibition of FAAH leads to an accumulation of anandamide in the CNS and periphery where it activates cannabinoid receptors. EX-597 has been found to elevate anandamide levels and have activity against neuropathic pain in a mouse model.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).